Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

The New England journal of medicine - 22 May 2014

Poordad Fred, Hezode Christophe, Trinh Roger, Kowdley Kris V, Zeuzem Stefan, Agarwal Kosh, Shiffman Mitchell L, Wedemeyer Heiner, Berg Thomas, Yoshida Eric M, Forns Xavier, Lovell Sandra S, Da Silva-Tillmann Barbara, Collins Christine A, Campbell Andrew L, Podsadecki Thomas, Bernstein Barry

Abstract excerpt

BACKGROUND: Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Proline

Share to Sulfonamides

Share to Valine

Source

Identifiers

PMID: 24725237
DOI: 10.1056/NEJMoa1402869

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24725237-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.PMID 24725237Read ↗

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.Semantic proximity Read ↗

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.Semantic proximity Read ↗

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.Semantic proximity Read ↗

Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.Semantic proximity Read ↗

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.Semantic proximity Read ↗

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.Semantic proximity Read ↗

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.Semantic proximity Read ↗

Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.Semantic proximity Read ↗

[Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.